1. Protein Tyrosine Kinase/RTK
  2. ALK

ALK

ALK (Anaplastic lymphoma kinase) is encoded by the ALK gene. ALK is a membrane associated tyrosine kinase receptor of the insulin receptor superfamily. The function of the full-length ALK receptor is poorly understood. It has a probable role in the central and peripheral nervous system development and maintenance. ALK is a dependence receptor, which may exert antagonist functions, proapoptotic or antiapoptotic, depending on the absence or presence of a ligand. Dependence receptors have a potential role in cancer and development. Ligands available for this demonstration were agonist anti-ALK antibodies. ALK is still an orphan receptor, given the high level of controversy about pleiotrophin and midkine.

ALK Related Products (29):

Cat. No. Product Name Effect Purity
  • HY-50878
    Crizotinib Inhibitor 99.97%
    Crizotinib is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
  • HY-12857
    Brigatinib Inhibitor 99.86%
    Brigatinib is a highly potent and selective ALK inhibitor, with IC50 of 0.6 nM.
  • HY-12215
    PF-06463922 Inhibitor 99.83%
    PF-06463922 is a potent, dual ALK/ROS1 inhibitor, with Ki of < 0.02 nM, < 0.07 nM, and 0.7 nM for ROS1, ALK (WT), and ALK (L1196M), respectively.
  • HY-15656
    LDK378 Inhibitor 99.95%
    LDK378 is a potent and more specific ALK inhibitor with IC50 of 0.2 nM.
  • HY-13011
    CH5424802 Inhibitor 99.34%
    CH5424802 is a potent, selective, and orally available ALK inhibitor with IC50 of 1.9 nM, the dissociation constant (KD) value for ALK in an ATP-competitive manner is 2.4 nM using a competition-binding assay.
  • HY-103714A
    X-396 hydrochloride Inhibitor 98.51%
    X-396 hydrochloride is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively.
  • HY-112140
    JH-VIII-157-02 Inhibitor 98.86%
    JH-VIII-157-02 is a structural analogue of alectinib, acts as an ALK inhibitor, and shows an IC50 of 2 nM for echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) G1202R in cells.
  • HY-111482
    SM 16 Inhibitor
    SM 16 is a ALK5/ALK4 kinase inhibitor with Kis of 10 and 1.5 nM, respectively.
  • HY-12678
    Entrectinib Inhibitor 99.61%
    Entrectinib is a potent and orally available Trk, ROS1, and ALK inhibitor; inhibits TrkA, TrkB, TrkC, ROS1 and ALK with IC50 values of 1, 3, 5, 12 and 7 nM, respectively.
  • HY-50878A
    Crizotinib hydrochloride Inhibitor 99.86%
    Crizotinib hydrochloride is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
  • HY-13011A
    CH5424802 Hydrochloride Inhibitor 99.95%
    CH5424802 Hydrochloride is a potent, selective, and orally available ALK inhibitor with IC50 of 1.9 nM, the dissociation constant (KD) value for ALK in an ATP-competitive manner is 2.4 nM using a competition-bind assay.
  • HY-10192
    NVP-TAE 684 Inhibitor 99.40%
    NVP-TAE 684 is a highly potent and selective ALK inhibitor, which blocks the growth of ALCL-derived and ALK-dependent cell lines with IC50 values between 2 and 10 nM.
  • HY-15656A
    LDK378 dihydrochloride Inhibitor 99.86%
    LDK378 2Hcl (Ceritinib) is potent inhibitor against ALK with IC50 of 0.2 nM, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively.
  • HY-16590
    X-376 Inhibitor 98.02%
    X-376 is a potent and dual ALK/MET inhibitor with IC50s of 0.61 nM and 0.69 nM, respectively.
  • HY-15609
    AZD-3463 Inhibitor 98.49%
    AZD-3463 is an ALK/IGF1R inhibitor which overcomes multiple mechanisms of acquired resistance to crizotinib.
  • HY-15841
    CEP-37440 Inhibitor 99.87%
    CEP-37440 is a novel potent and selective Dual FAK/ALK inhibitor with IC50 s of 2.3 nM (FAK) and 120 nM(ALK cellular IC50 in 75% human plasma).
  • HY-13326
    ASP3026 Inhibitor 99.76%
    ASP3026 is a novel and selective inhibitor for ALK (anaplastic lymphoma kinase) with IC50 of 3.5 nM.
  • HY-103022
    TPX-0005 Inhibitor 99.91%
    TPX-0005 is a potent ALK/ROS1/TRK inhibitor, with IC50 of 5.3 nM, 1.01 nM, 1.26 nM and 1.08 nM for SRC, WT ALK, ALK G1202R and ALK L1196M, respectively.
  • HY-13464
    ALK-IN-1 Inhibitor 99.96%
    ALK-IN-1 is a potent and selective active inhibitor of anaplastic lymphoma kinase(ALK), Patent US20140066406 A1.
  • HY-13020
    GSK1838705A Inhibitor 98.99%
    GSK1838705A is a potent and reversible IGF-IR and the insulin receptor inhibitor with IC50s of 2.0 and 1.6 nM, respectively. It also inhibits ALK with an IC50 of 0.5 nM.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.